11.62SEK-0.68%Mkt Cap: 3.27B SEKP/E: —Last update: 2026-06-01
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap3.27B SEK
Enterprise Value2.20B SEK
Revenue (TTM)3.53M SEK
Gross Profit3.82M SEK
Net Income (TTM)-477.47M SEK
Revenue/Share0.0140 SEK
Last Price11.62 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees37
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.09
PEG—
EV/EBITDA—
EV/Revenue623.39
P/S933.90
P/B3.29
EPS (TTM)-1.90
EPS (Forward)-1.92
52W Range
7.35063% of range14.10
52W High14.10 SEK
52W Low7.350 SEK
Profitability
Gross Margin100.00%
Oper. Margin-17921.43%
EBITDA Margin0.00%
Profit Margin-12509.14%
ROE-43.59%
ROA-39.18%
Growth
Revenue Growth-32.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-375.74M SEK
CapEx (TTM)—
FCF Margin-6724.82%
FCF Yield-7.25%
Net Debt-1.06B SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio12.69
Quick Ratio12.57
Book Value/Sh3.558 SEK
Cash/Share3.805 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)29.50 SEK
Target Range15.00 SEK – 40.00 SEK
# Analysts6
Ownership
Shares Out.281.53M
Float196.49M
Insiders12.73%
Institutions56.57%
Technical
SMA 5010.51 (+10.6%)
SMA 20010.82 (+7.4%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)560.87K
Avg Vol (10d)654.34K
Technical Indicators
RSI (14)57.8
MACD0.4255
MACD Signal0.3604
MACD Hist.+0.0651
BB Upper12.59 SEK
BB Middle11.12 SEK
BB Lower9.645 SEK
BB Width26.50%
ATR (14)0.5794 SEK
Vol Ratio (20d)2.00x